Gene and cell therapy group
Revenue surged 139 per cent to £81.3m in the six months to 30 June, from £34m in the same period last year – mainly due to its bioprocessing and commercial revenue.
“Exceptional growth was seen in bioprocessing and commercial development,” the biotech group said in a statement this morning, which had revenue swell 223 per cent to £75.6m.
The news sent shares jumping 10.5 per cent to a total share price of 1,634.00 by late afternoon.
Operational costs also shrank 19 per cent to £23.6m in the period, which
Chief executive
“The exceptional financial results that we have reported reflect our strong progress across the business as we continue to demonstrate our world leading expertise in gene and cell therapy.”
The biotech boss added that, as the group moves “from strength to strength”, it is in a “great position to maximise on the opportunities ahead”.
The post Covid-19 vaccine maker
© City AM, source